Research Shows How Talc Powder May Change Ovarian Cancer Cells
Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
Ovarian Cancer
Boost in Frontline Bevacizumab Use in Ovarian Cancer Linked to Guidelines Inclusion
Addition of bevacizumab to NCCN guidelines as a frontline therapy in ovarian cancer spurred more utilization of the drug than did fresh findings from clinical trials.
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
Intraperitoneal Chemotherapy Fails to Improve Outcomes in Advanced Ovarian Carcinoma
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
More accurate biomarkers are needed to better define subgroups of patients with ovarian cancer who are most likely to benefit from late-line niraparib.
Genetic Testing Underused in Breast, Ovarian Cancer
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
Dendritic Cell Vaccination in Ovarian Cancer May Induce Long-Lasting Antitumor Immunity
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Pembrolizumab Plus Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Next post in Gastrointestinal Cancers
